Osteoporosis in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 9, 2010, Pages 1031-1043

  Hearn, Andrew P ^a   Silber, Eli ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Queen Elizabeth Hospital   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

clinical guideline; multiple sclerosis; osteoporosis

Indexed keywords

ALENDRONIC ACID; ALUMINUM; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BAZEDOXIFENE; BETA INTERFERON; CALCITONIN; CALCIUM; CYCLOSPORIN; DENOSUMAB; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; GONADORELIN AGONIST; IBANDRONIC ACID; LITHIUM; METHOTREXATE; METHYLPREDNISOLONE; PARATHYROID HORMONE[1-34]; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; THYROXINE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

ALGORITHM; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEVELOPED COUNTRY; DRUG MEGADOSE; FALLING; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MOBILIZATION; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SIDE EFFECT;

ACCIDENTAL FALLS; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANIMALS; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77956299584     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510368985     Document Type: Review

References (60)

1. Hauser SL, Goodin DS Multiple sclerosis and other dymelinating disorders. In: Fauci AS, Braunwald E, Kasper DL, et al. (eds) Harrison's principles of internal medicine. Vol II, 17 th edn. New York: McGraw Hill Medical, 2008, p. 2611-2621.
2. Wilkinson I., Lennox G. Multiple sclerosis. In: Wilkinson I, Lennox G (eds) Essential neurology. 4 th edn. Oxford: Blackwell, 2005, p. 99-109.
3. Compston A., Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
4. Lindsay R., Cosman F. Osteoporosis. In: Fauci AS, Braunwald E, Kasper DL, et al. (eds) Harrison's principles of internal medicine. Vol II, 17th edn. New York: McGraw Hill Medical, 2008, p. 2397-2408.
5. Sambrook P., Cooper C. Osteoporosis. Lancet 2006 ; 367: 2010-2018.
6. Sharma S., Fraser M., Lovell F., Reece A., McLellan AR Characteristics of males over 50 years who present with a fracture - epidemiology and underlying risk factors. J Bone Joint Surg Br 2008 ; 90B: 72-77.
7. Marrie RA, Cutter G., Tyry T., Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology 2009 ; 73: 1394-1398.
8. Weinstock-Guttman B., Gallagher E., Baier M., et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004 ; 10: 170-175.
9. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996 ; 53: 753-757.
10. Tuzun S., Altintas A., Karacan I., Tangurek S., Saip S., Siva A. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler 2003 ; 9: 600-604.
11. Formica CA, Cosman F., Nieves J., Herbert J., Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int 1997 ; 61: 129-133.
12. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin-D veficiency and reduced bone mass in multiple-sclerosis. Neurology 1994 ; 44: 1687-1692.
13. Cosman F., Nieves J., Komar L., et al. Fracture history and bone loss in patients with MS. Neurology 1998 ; 51: 1161-1165.
14. Ozgocmen S., Bulut S., Ilhan N., Gulkesen A., Ardicoglu O., Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 2005 ; 23: 309-313.
15. Zorzon M., Zivadinov R., Locatelli L., et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005 ; 12: 550-556.
16. Achiron A., Edelstein S., Ziev-Ner Y., Givon U., Rotstein Z., Barak Y. Bone strength in multiple sclerosis: cortical midtibial speed-of-sound assessment. Mult Scler 2004 ; 10: 488-493.
17. Berris KK, Repp AL, Kleerekoper M. Glucocorticoid- induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2007 ; 14: 446-450.
18. De Vries F., Bracke M., Leufkens HGA, Lammers JWJ, Cooper C., van Staa TP Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007 ; 56: 208-214.
19. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High-dose glucocorticoids in multiple-sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994 ; 9: 1097-1105.
20. Takata S., Yasui N. Disuse osteoporosis. J Med Invest 2001 ; 48: 147-156.
21. Chen JS, Cameron ID, Cumming RG, et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 2006 ; 21: 324-331.
22. Bikle DD, Halloran BP The response of bone to unloading. J Bone Miner Metab 1999 ; 17: 233-244.
23. Heer M., Baecker N., Mika C., Boese A., Gerzer R. Immobilization induces a very rapid increase in osteoclast activity. Acta Astronaut 2005 ; 57: 31-36.
24. Bieringsorensen F., Bohr HH, Schaadt OP Longitudinal-study of bone-mineral content in the lumbar spine, the forearm and the lower-extremities after spinal-cord injury. Eur J Clin Invest 1990 ; 20: 330-335.
25. Leslie WD, Nance PW Dissociated hip and spine demineralization - a specific finding in spinal-cord injury. Arch Phys Med Rehabil 1993 ; 74: 960-964.
26. Maimoun L., Fattal C., Micallef JP, Peruchon E., Rabischong P. Bone loss in spinal cord-injured patients: from physiopathology to therapy. Spinal Cord 2006 ; 44: 203-210.
27. DelPuente A., Pappone N., Mandes MG, Mantova D., Scarpa R., Oriente P. Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int 1996 ; 6: 50-54.
28. Poole KES, Reeve J., Warburton EA Falls, fractures, and osteoporosis after stroke - time to think about protection? Stroke 2002 ; 33: 1432-1436.
29. LaBan MM, Martin T., Pechur J., Sarnacki S. Physical and occupational therapy in the treatment of patients with multiple sclerosis. Phys Med Rehabil Clin N Am 1998 ; 9: 603-614.
30. Cattaneo D., De Nuzzo C., Fascia T., Macalli M., Pisoni I., Cardini R. Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 2002 ; 83: 864-867.
31. Finlayson ML, Peterson EW, Cho CC Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 2006 ; 87: 1274-1279.
32. Logan WC, Sloane R., Lyles KW, Goldstein B., Hoenig HM Incidence of fractures in a cohort of veterans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil 2008 ; 89: 237-243.
33. Mundy GR Osteoporosis and inflammation. Nutr Rev 2007 ; 65: S147-151.
34. Kurban S., Akpinar Z., Mehmetoglu I. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 2008 ; 14: 431-432.
35. Scatena M., Liaw L., Giachelli CM Osteopontin - a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007 ; 27: 2302-2309.
36. Altintas A., Saruhan-Direskeneli G., Benbir G., Demir M., Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 2008 ; 276: 41-44.
37. Comabella M., Pericot I., Goertsches R., et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005 ; 158: 231-239.
38. Hur EM, Youssef S., Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature Immunol 2007 ; 8: 74-83.
39. Chabas D., Baranzini SE, Mitchell D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001 ; 294: 1731-1735.
40. St-Arnaud R. The direct role of vitamin D on bone homeostasis. Arch Biochem Biophys 2008 ; 473: 225-230.
41. Lyngstad-Brechan MA, Tauboll E., Nakken KO, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 2008 ; 68: 759-766.
42. Pack AM, Walczak TS Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 2008 ; 83: 305-328.
43. El-Hajj Fuleihan G., Dib L., Yamout B., Sawaya R., Mikati MA Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008 ; 43: 149-155.
44. Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E., Orwoll ES Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008 ; 71: 723-730.
45. Kumandas S., Koklu E., Gumus H., et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 2006 ; 19: 529-534.
46. Farhat G., Yamout B., Mikati MA, Demirjian S., Sawaya R., El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002 ; 58: 1348-1353.
47. Takkouche B., Montes-Martinez A., Gill SS, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007 ; 30: 171-184.
48. Weinstock-Guttman B., Hong J., Sontos R., et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler 2006 ; 12: 541-550.
49. National Institute for Clinical Excellence. Multiple sclerosis. Clinical guidelines 8. 2003 ; London, England.
50. Peterson EW, Cho CC, von Koch L., Finlayson ML Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 2008 ; 89: 1031-1037.
51. Miller PD Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008 ; 22: 849-868.
52. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: National Institute for Health and Clinical Excellence, 2008.
53. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: National Institute for Health and Clinical Excellence, 2008.
54. National Institute for Clinical Excellence. 'Osteoporosis', http://guidance.nice.org.uk/CG/Wave7/32 (2009, accessed July 2009).
55. FRAX® WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/ index.htm.
56. Compston J., Cooper A., Cooper C., et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009 ; 62: 105-108.
57. Brown SA, Guise TA Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol 2007 ; 4: 310-320.
58. Royal College of Physicians, Bone and Tooth Society, and Society NO. Glucocorticoid induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians of London, 2002.
59. British National Formulary. British National Formulary 54. In: 54 edn. London: BMJ Publishing Group, RPS Publishing, 2007, p. 517.
60. Di Munno O., Mazzantini M., Sinigaglia L., et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 2004 ; 31: 1305-1309.